NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the h...
NewCardio reported revenue of $257,399 for fiscal year 2010, and net income of -$11.50 million. In Q3 2011 (the quarter ended September 30, 2011) revenue was $9,883, down 90.0% from a year before. Its market capitalization was $3,314 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2010; market data as of October 8, 2026.
No profile data available.